amgn cut 300 jobs in South San Francisco# Stock
d*0
1 楼
Amgen to cut about 300 jobs, close one building in South San Francisco
http://www.marketwatch.com/story/amgen-to-cut-about-300-jobs-cl
Amgen Inc. plans to cut about 300 jobs and close one of its buildings in
South San Francisco as part of a reorganization that will combine the
biotech’s cancer organization with one it acquired by buying Onyx
Pharmaceuticals.
The shine on Amgen’s AMGN, -0.01% $10.4 billion acquisition of Onyx
Pharmaceuticals -- and the cancer drug Kyprolis that was its crown jewel --
brightened recently after a company-sponsored study found that Kyprolis
patients lived twice as long as patients taking the rival treatment Velcade
before their multiple myeloma worsened.
Yet Amgen, of Thousand Oaks, Calif., has been laying off employees and
closing buildings as it launches some new drugs and prepares for more. The
company is also facing competition for some of its drugs and from an
activist investor, Daniel Loeb, whose Third Point LLC fund took a stake in
Amgen last year and recommended reducing what it termed the company’s “
bloated cost structure.”
In a memo to staff on Tuesday, Amgen CEO Robert Bradway said 300 Onyx jobs
would be cut and Onyx’s South San Francisco headquarters building would be
shuttered. “These combined oncology capabilities will create the focus and
efficiency Amgen requires to progress our vision in oncology, and to remain
a world leader for the long term,” he wrote.
The cuts, first reported by Xconomy, are part of a larger reorganization
that will merge the two companies’ cancer teams into a single organization,
Bradway wrote. He said he expects Amgen to retain all of Onyx’s sales and
medical staff, while shifting some Onyx researchers to Amgen’s own South
San Francisco laboratories.
http://www.marketwatch.com/story/amgen-to-cut-about-300-jobs-cl
Amgen Inc. plans to cut about 300 jobs and close one of its buildings in
South San Francisco as part of a reorganization that will combine the
biotech’s cancer organization with one it acquired by buying Onyx
Pharmaceuticals.
The shine on Amgen’s AMGN, -0.01% $10.4 billion acquisition of Onyx
Pharmaceuticals -- and the cancer drug Kyprolis that was its crown jewel --
brightened recently after a company-sponsored study found that Kyprolis
patients lived twice as long as patients taking the rival treatment Velcade
before their multiple myeloma worsened.
Yet Amgen, of Thousand Oaks, Calif., has been laying off employees and
closing buildings as it launches some new drugs and prepares for more. The
company is also facing competition for some of its drugs and from an
activist investor, Daniel Loeb, whose Third Point LLC fund took a stake in
Amgen last year and recommended reducing what it termed the company’s “
bloated cost structure.”
In a memo to staff on Tuesday, Amgen CEO Robert Bradway said 300 Onyx jobs
would be cut and Onyx’s South San Francisco headquarters building would be
shuttered. “These combined oncology capabilities will create the focus and
efficiency Amgen requires to progress our vision in oncology, and to remain
a world leader for the long term,” he wrote.
The cuts, first reported by Xconomy, are part of a larger reorganization
that will merge the two companies’ cancer teams into a single organization,
Bradway wrote. He said he expects Amgen to retain all of Onyx’s sales and
medical staff, while shifting some Onyx researchers to Amgen’s own South
San Francisco laboratories.